DuPont de Nemours Inc vs Smith & Nephew plc — how do they compare? DuPont de Nemours Inc trades at $144.49 (market cap $19.51B), while Smith & Nephew plc trades at $29.78 (market cap $12.54B). The key difference: DuPont de Nemours Inc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| DD | SNN | |
|---|---|---|
Market Cap | $19.51B | $12.54B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $38.70 |
52-Week Low | $90.24 | $28.73 |
Enterprise Value | $20.90B | $15.57B |
Dividend Yield | 1.66% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $141.56, down 0.65% over the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and aerospace demand, leading to a raised full-year 2026 outlook. The stock exhibits a high P/E ratio of 62.01, reflecting growth expectations, while net income margin remains thin at 0.79%.
Outlook is positive due to earnings momentum and strategic initiatives in water treatment and lithium extraction, but risks include legal settlements over PFAS chemicals and volatile cash flows. With a consensus price target of $232.80 implying significant upside, the stock offers growth potential tempered by execution and regulatory challenges.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Trailing returns across standard periods
Latest headlines on both assets
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →